All Relations between asymmetrical (pato 0000616) and nitrogen monoxide

Reference Sentence Publish Date Extraction Date Species
Caroline L Smith, Shelagh Anthony, Mike Hubank, James M Leiper, Patrick Vallanc. Effects of ADMA upon gene expression: an insight into the pathophysiological significance of raised plasma ADMA. PLoS medicine vol 2 issue 10 2006 16190779 asymmetric dimethylarginine (adma) is a naturally occurring inhibitor of nitric oxide synthesis that accumulates in a wide range of diseases associated with endothelial dysfunction and enhanced atherosclerosis. 2006-05-18 2022-01-12 Not clear
Jun Wang, Ah Siew Sim, Xing Li Wang, Chris Salonikas, Daya Naidoo, David E L Wilcke. Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease. Atherosclerosis vol 184 issue 2 2006 15939423 elevated plasma levels of asymmetric dimethylarginine (adma), an endogenous inhibitor of nitric oxide production, are reported to be associated with coronary artery disease (cad). 2006-04-20 2022-01-12 Not clear
Jens Martens-Lobenhoffer, Stefanie M Bode-B\\xc3\\xb6ge. Fast and efficient determination of arginine, symmetric dimethylarginine, and asymmetric dimethylarginine in biological fluids by hydrophilic-interaction liquid chromatography-electrospray tandem mass spectrometry. Clinical chemistry vol 52 issue 3 2006 16384887 nitric oxide is synthesized from the amino acid arg by the enzyme endothelial nitric oxide synthase, which is competitively inhibited by the arginine metabolite asymmetric dimethylarginine (adma). 2006-04-13 2022-01-12 Not clear
Caroline L Smith, Patrick Vallanc. Cardiovascular tests: use & limits of biochemical markers - therapeutic measurements of ADMA involved in cardiovascular disorders. Current pharmaceutical design vol 11 issue 17 2006 16026287 asymmetric dimethylarginine (adma) is an endogenously occurring methylarginine that inhibits nitric oxide synthesis. 2006-04-10 2022-01-12 Not clear
Robert A Augustyniak, Ronald G Victor, Donald A Morgan, Weiguo Zhan. L-NAME- and ADMA-induced sympathetic neural activation in conscious rats. American journal of physiology. Regulatory, integrative and comparative physiology vol 290 issue 3 2006 16239367 although studies in anesthetized, sino-aortic denervated animals indicate that inhibition of central nitric oxide (no) causes an excitatory influence on efferent sympathetic nerve activity (sna) that is normally offset by baroreflex activation, studies in conscious animals have not provided clear-cut evidence for a sympathoexcitatory effect of n(omega)-nitro-l-arginine methyl ester (l-name) or the endogenous circulating no synthase (nos) inhibitor asymmetric dimethylarginine (adma). 2006-04-03 2022-01-12 Not clear
M O Verhoeven, M Hemelaar, M J van der Mooren, P Kenemans, T Teerlin. Oral, more than transdermal, oestrogen therapy lowers asymmetric dimethylarginine in healthy postmenopausal women: a randomized, placebo-controlled study. Journal of internal medicine vol 259 issue 2 2006 16420549 to compare the effects of oral and transdermal hormone therapy (ht) on asymmetric dimethylarginine (adma), an endogenous inhibitor of nitric oxide synthase, in postmenopausal women. 2006-02-28 2022-01-12 Not clear
Soni Pullamsetti, Ladislau Kiss, Hossein Ardeschir Ghofrani, Robert Voswinckel, Peter Haredza, Walter Klepetko, Clemens Aigner, Ludger Fink, Jai Prakash Muyal, Norbert Weissmann, Friedrich Grimminger, Werner Seeger, Ralph Theo Schermul. Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB journal : official publication of the Federation of American Societies for Experimental Biology vol 19 issue 9 2006 15827267 asymmetric dimethylarginine (adma) is an endogenous inhibitor of nitric oxide synthase (nos) and has been implicated in endothelial dysfunction. 2006-02-23 2022-01-12 Not clear
Paloma Lluch, Maria D Mauricio, Jos\\xc3\\xa9 M Vila, Gloria Segarra, Pascual Medina, Juan A Del Olmo, Jos\\xc3\\xa9 M Rodrigo, Miguel A Serr. Accumulation of symmetric dimethylarginine in hepatorenal syndrome. Experimental biology and medicine (Maywood, N.J.) vol 231 issue 1 2006 16380646 in patients with cirrhosis, nitric oxide (no), asymmetric dimethylarginine (adma), and possibly symmetric dimethylarginine (sdma) have been linked to the severity of the disease. 2006-02-16 2022-01-12 Not clear
Hisanori Morimoto, Kazushi Nakao, Kousuke Fukuoka, Ai Sarai, Ai Yano, Takashi Kihara, Shinji Fukuda, Jun Wada, Hirofumi Makin. Long-term use of vitamin E-coated polysulfone membrane reduces oxidative stress markers in haemodialysis patients. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association vol 20 issue 12 2006 16221689 asymmetric dimethylarginine (adma) is an endogenous inhibitor of nitric oxide synthase and an independent predictor of overall mortality and cardiovascular outcome in haemodialysis (hd) patients. 2006-02-14 2022-01-12 Not clear
Makoto Tsunoda, Satoko Nonaka, Takashi Funats. Determination of methylated arginines by column-switching high-performance liquid chromatography-fluorescence detection. The Analyst vol 130 issue 10 2006 16172667 a column-switching high-performance liquid chromatography (hplc)-fluorescence detection method for the determination of three methylated arginines, n(g)-monomethyl-l-arginine (l-nmma), n(g),n(g)-dimethyl-l-arginine (asymmetric dimethyl-l-arginine, adma), and n(g),n(g)'-dimethyl-l-arginine (symmetric dimethyl-l-arginine, sdma), which are endogenous nitric oxide synthase inhibitors, was developed. 2006-02-09 2022-01-13 Not clear
Prabath W B Nanayakkara, Tom Teerlink, Coen D A Stehouwer, Daud Allajar, Annemieke Spijkerman, Casper Schalkwijk, Piet M ter Wee, Coen van Guldene. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney international vol 68 issue 5 2006 16221223 in patients with end-stage renal disease, increased serum concentration of asymmetric dimethylarginine (adma), an endogenous inhibitor of nitric oxide synthase (nos), has been linked to excess cardiovascular morbidity. 2006-01-20 2022-01-12 Not clear
Ruth L Stornetta, Diane L Rosin, Johnny R Simmons, Travis J McQuiston, Nina Vujovic, Matthew C Weston, Patrice G Guyene. Coexpression of vesicular glutamate transporter-3 and gamma-aminobutyric acidergic markers in rat rostral medullary raphe and intermediolateral cell column. The Journal of comparative neurology vol 492 issue 4 2006 16228993 vglut3-ir terminals formed approximately equal numbers of symmetric and asymmetric synapses onto presumed preganglionic neurons (nitric oxide synthase-ir profiles) or gaba-ir dendrites in iml, and terminals immunoreactive for both vglut3 and gaba always formed symmetric synapses. 2006-01-19 2022-01-12 Not clear
Judit Zsuga, Rudolf Gesztelyi, J\\xc3\\xa1nos T\\xc3\\xb6r\\xc3\\xb6k, S\\xc3\\xa1ndor K\\xc3\\xa9ki, D\\xc3\\xa1niel Bereczk. Asymmetric dimethylarginine: a molecule responsible for the coexistence of insulin resistance and atherosclerosis via dual nitric oxide synthase inhibition. Medical hypotheses vol 65 issue 6 2006 16125868 asymmetric dimethylarginine: a molecule responsible for the coexistence of insulin resistance and atherosclerosis via dual nitric oxide synthase inhibition. 2006-01-05 2022-01-13 Not clear
Judit Zsuga, Rudolf Gesztelyi, J\\xc3\\xa1nos T\\xc3\\xb6r\\xc3\\xb6k, S\\xc3\\xa1ndor K\\xc3\\xa9ki, D\\xc3\\xa1niel Bereczk. Asymmetric dimethylarginine: a molecule responsible for the coexistence of insulin resistance and atherosclerosis via dual nitric oxide synthase inhibition. Medical hypotheses vol 65 issue 6 2006 16125868 asymmetric dimethylarginine (adma) has been recently identified as the major endogenous inhibitor of soluble nitric oxide synthase. 2006-01-05 2022-01-13 Not clear
Tian-Lun Yang, Mei-Fang Chen, Bai-Lin Luo, Qi-Ying Xie, Jun-Lin Jiang, Yuan-Jian L. Fenofibrate decreases asymmetric dimethylarginine level in cultured endothelial cells by inhibiting NF-kappaB activity. Naunyn-Schmiedeberg's archives of pharmacology vol 371 issue 5 2006 15915325 previous investigations have demonstrated that endogenous inhibitors of nitric oxide synthase (nos), such as asymmetric dimethylarginine (adma), contribute importantly to endothelial dysfunction, and that fenofibrate has a protective effect on the endothelium in rats treated with low-density lipoprotein (ldl) by reducing adma levels. 2006-01-05 2022-01-12 Not clear
Maurizio Marra, Anna Rita Bonfigli, Patrizia Bonazzi, Renato Galeazzi, Cristina Sirolla, Ivano Testa, Stefano Cenerelli, Massimo Boemi, Roberto Test. Asymptomatic Helicobacter pylori infection increases asymmetric dimethylarginine levels in healthy subjects. Helicobacter vol 10 issue 6 2006 16302987 increasing evidences have pointed out that the endogenous inhibitor of nitric oxide synthase, asymmetric dimethylarginine, defined as a risk factor for cardiovascular disease, may increase in infections and plays an important role impairing the vascular functions of the endothelium. 2006-01-03 2022-01-12 Not clear
Thomas Thum, Dimitrios Tsikas, Sylvia Stein, Maximilian Schultheiss, Martin Eigenthaler, Stefan D Anker, Philip A Poole-Wilson, Georg Ertl, Johann Bauersach. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. Journal of the American College of Cardiology vol 46 issue 9 2005 16256870 suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. 2005-12-29 2022-01-12 Not clear
Alessandra Testa, Belinda Spoto, Giovanni Tripepi, Francesca Mallamaci, Lorenzo Malatino, Pasquale Fatuzzo, Renke Maas, Rainer Boeger, Carmine Zoccal. The GLU298ASP variant of nitric oxide synthase interacts with asymmetric dimethyl arginine in determining cardiovascular mortality in patients with end-stage renal disease. Journal of hypertension vol 23 issue 10 2005 16148605 the glu298asp variant of nitric oxide synthase interacts with asymmetric dimethyl arginine in determining cardiovascular mortality in patients with end-stage renal disease. 2005-12-21 2022-01-13 Not clear
Alessandra Testa, Belinda Spoto, Giovanni Tripepi, Francesca Mallamaci, Lorenzo Malatino, Pasquale Fatuzzo, Renke Maas, Rainer Boeger, Carmine Zoccal. The GLU298ASP variant of nitric oxide synthase interacts with asymmetric dimethyl arginine in determining cardiovascular mortality in patients with end-stage renal disease. Journal of hypertension vol 23 issue 10 2005 16148605 impaired nitric oxide generation and accumulation of the endogenous inhibitor of nitric oxide synthase (nos), asymmetric dimethylarginine (adma), have been identified as strong predictors of cardiovascular outcomes in patients with end-stage renal disease (esrd). 2005-12-21 2022-01-13 Not clear
Kazushi Tsuda, Ichiro Nishi. An association between plasma asymmetric dimethylarginine and membrane fluidity of erythrocytes in hypertensive and normotensive men: an electron paramagnetic resonance investigation. American journal of hypertension vol 18 issue 9 Pt 1 2005 16182117 evidence indicates that increased levels of asymmetric dimethylarginine (adma), an endogenous inhibitor of nitric oxide (no) synthase, are associated with increased risk of vascular dysfunction. 2005-12-21 2022-01-12 Not clear
Page: 
1   2   3   4   5   6   7   8   9   10   11   12   13   14   15   16   17   18   19   20   21   22   23   24   25   26   27   28   29   30   31   32   33   34   35   36   37   38   39   40   41   42   43   44   45   46   47   48   49   50   51   52   53   54